CARISMA THERAPEUTICS INC CARM
COM · Common Stock · CUSIP 14216R101
1
institutional holders
-2 vs Q1 2026
785
shares reported held*
$4reported value*
0 new
0 added
0 reduced
2 sold out
net sold ≈ $7.5k (-1.5m shares)
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $0.01.
Trends to Q2 2026
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q1 2023 | 37 |
| Q2 2023 | 54 |
| Q3 2023 | 59 |
| Q4 2023 | 51 |
| Q1 2024 | 52 |
| Q2 2024 | 55 |
| Q3 2024 | 38 |
| Q4 2024 | 42 |
| Q1 2025 | 38 |
| Q2 2025 | 37 |
| Q3 2025 | 33 |
| Q4 2025 | 7 |
| Q1 2026 | 3 |
| Q2 2026 | 1 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Bought or addedCut or sold out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q3 2024 | 10 | 31 |
| Q4 2024 | 13 | 17 |
| Q1 2025 | 10 | 12 |
| Q2 2025 | 9 | 13 |
| Q3 2025 | 6 | 9 |
| Q4 2025 | 2 | 28 |
| Q1 2026 | 1 | 4 |
| Q2 2026 | 0 | 2 |
Biggest buyers
| None |
Biggest sellers
| Merck & Co., Inc. | Sold out | -1.5m |
| Ascentis Independent Advisors | Sold out | -200 |
Holders, Q2 2026
| Manager | Shares | Change |
|---|---|---|
| Union Bancaire Privee, UBP SA 0.00% of their portfolio | 785 $4 | Unchanged |